SAJA licensing deal with Novartis
Licensing deal with Novartis
SAJA announced signing a contract on 15th December 2015 at SAJA headquarter with Novartis AG to launch SAJA first anti diabetic drug (Jalra® and Jalra M®) as a second brand of Novartis AG blockbuster (Galvus® and Galvus met®).
By signing this agreement, both companies shall be allies in fighting diabetes that affects around 20.6% of adults in Saudi Arabia.
The contract also covers a secondary packaging deal of some Novartis AG vital products in SAJA manufacturing facility which reflects the trust in SAJA facilities’ state of the art quality.